ShareValue scores for IAM: Valuation 50, Quality 41, Growth 50, Health 54.
IAMNASDAQ
Iambic Therapeutics, Inc. Common Stock
$11.64
(-13.13%)
Updated
IAMNASDAQ
Iambic Therapeutics, Inc. Common Stock
Updated
Pulse
Pulse
Fundamental Rating
Value Trap Risk
If P/E met sector median
Rating
Trap Risk
P/E to median
Company Details
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
Score Analysis
AI Investment Thesis
Valuation looks fairly valued: P/S of 42.44 sits roughly eight times the 5.3 sector average, but that premium reflects a pre-revenue clinical-stage platform, not earnings, so the multiple is a weak anchor.
The most decision-relevant fundamental is the absence of product revenue and profitability, so the $150M IPO proceeds, not earnings, fund the pipeline.
On October 14, 2026 Iambic priced its Nasdaq IPO at $16.00, raising $150M gross and closing October 16, giving roughly two years of runway.